Drugs / IMMU-114
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01728207 | Mar 2013 → Mar 2017 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | Gilead Sciences | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMMU-114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01728207 ↗ |
| Route | Subcutaneous | “IMMU-114 will be administered subcutaneously (under the skin)” NCT01728207 ↗ |